Hydration is essential for both safety and comfort
People who crashed at 2.5 mg on day one often sail through 2.0 mg after a proper microdose ramp-up
The most extensively studied compounds are exenatide (Byetta [Amylin Pharmaceuticals, San Diego, CA], which has been approved by the US Food and Drug Administration [FDA] for the treatment of type 2 diabetes), liraglutide (Victoza [Novo Nordisk, Princeton, NJ], which has been submitted to the FDA for approval), sitaglitptin (Januvia [Abbott Laboratories, Abbott Park, IL], which has been approved by the FDA for type 2 diabetes), and vildagliptin (Galvus [Novo Nordisk, Princeton, NJ], which has been submitted to FDA)
You can read the abstract of this article at LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM)
10.3389/fphar.2016.00433 [DOI] [PMC free article] [PubMed] [Google Scholar] Drucker D
Scheen AJ: Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors
